Xiaobin Wu Ph.D.
Net Worth
Last updated:
What is Xiaobin Wu Ph.D. net worth?
The estimated net worth of Dr. Xiaobin Wu Ph.D. is at least $36,016,037 as of 6 Dec 2024. He owns shares worth $831,195 as insider, has earned $27,804,842 from insider trading and has received compensation worth at least $7,380,000 in BeiGene, Ltd..
What is the salary of Xiaobin Wu Ph.D.?
Dr. Xiaobin Wu Ph.D. salary is $1,230,000 per year as Pres, Chief Operating Officer & GM of China in BeiGene, Ltd..
How old is Xiaobin Wu Ph.D.?
Dr. Xiaobin Wu Ph.D. is 63 years old, born in 1962.
What stocks does Xiaobin Wu Ph.D. currently own?
As insider, Dr. Xiaobin Wu Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| BeiGene, Ltd. (BGNE) | Pres, Chief Operating Officer & GM of China | 4,500 | $184.71 | $831,195 |
What does BeiGene, Ltd. do?
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Xiaobin Wu Ph.D. insider trading
BeiGene, Ltd.
Dr. Xiaobin Wu Ph.D. has made 53 insider trades between 2019-2024, according to the Form 4 filled with the SEC. Most recently he sold 0 units of BGNE stock on 6 Dec 2024.
The largest trade he's ever made was exercising 10,180 units of BGNE stock on 6 Jul 2021. As of 6 Dec 2024 he still owns at least 4,500 units of BGNE stock.
BeiGene, Ltd. key executives
BeiGene, Ltd. executives and other stock owners filed with the SEC:
- Dr. Edna Huang M.D. (52) Chief Medical Officer of Hematology
- Dr. Xiaobin Wu Ph.D. (63) Pres, Chief Operating Officer & GM of China
- Dr. Xiaodong Wang Ph.D. (62) Co-Founder, Chairman of the Scientific Advisory Board & Non-Executive Director
- Mr. John V. Oyler (57) Co-Founder, Executive Chairman & Chief Executive Officer